Phase III Melphalan Trial Shows Improvement in Hepatic-PFS in Melanoma Patients with Liver Metastases

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase III study of the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of melanoma patients with liver metastases, met its primary endpoint of hepatic progression-free survival.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login